Incorporation of RG1 epitope concatemers into a self-adjuvanting Flagellin-L2 vaccine broaden durable protection against cutaneous challenge with diverse human papillomavirus genotypes.

•L2 multimer formulated in alum elicits broad immunity against skin challenge lasting >1year.•Multimeric L2-TLR5 agonist fusion elicits immunity over 1year without exogenous adjuvant.•Passive transfer of L2 multimer-specific antiserum conveys broad immunity from skin challenge.•Inclusion of the L2 17-38 region in multi-HPV type fusions broadens the spectrum of protection.•Protection is mediated by sterilizing immunity.